Top

Published in:

01-06-2011 | Research

Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP

Authors: Zdravko Mitrović, Ivana Ilić, Igor Aurer, Sandra Bašić Kinda, Ivo Radman, Snježana Dotlić, Radmila Ajduković, Boris Labar

Published in: Pathology & Oncology Research | Issue 2/2011

Abstract

Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients’ outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients’ outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients. The expression of caspase-3 was also not associated with patients’ outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.

Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126PubMedCrossRef

Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391PubMedCrossRef

Cvetkovic RS, Perry CM (2006) Rituximab—a review of its use in Non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 66:791–820PubMedCrossRef

Guha M, Altieri DC (2009) Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 8:2708–2710PubMedCrossRef

Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRef

Watanuki-Miyauchi R, Kojima Y, Tsurumi H et al (2005) Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 55:324–330PubMedCrossRef

Karabatsou K, Pal P, Dodd S et al (2006) Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor alpha in primary central nervous system lymphoma. J Neurooncol 79:171–179PubMedCrossRef

Lin L, Min Z, Ping Z (2007) Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma 48:2179–2183CrossRef

Mainou-Fowler T, Overman LM, Dignum H et al (2008) A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol 32:59–68PubMed

10.

Adida C, Haioun C, Gaulard P et al (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921–1925PubMed

11.

Aktaş S, Kargi A, Olgun N et al (2009) Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr Virus positive and negative pediatric non-Hodgkin’s lymphoma. Pathol Oncol Res 15:345–350PubMedCrossRef

12.

Paydas S, Seydaoglu G, Ergin M et al (2009) Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res 33:1627–1635PubMedCrossRef

13.

Hans CP, Weisenburger DD, Greiner TC et al (2005) Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 18:1377–1384PubMedCrossRef

14.

Krajewski S, Gascoyne RD, Zapeta JM et al (1997) Immunolocalisation of the ICE/Ced 3-family protease, CPP32 (Caspase-3) in non-Hodgkin lymphomas, Chronic lymphocytic leukemias and reactive lymph nodes. Blood 89:3817–3825PubMed

15.

Donoghue S, Baden SH, Lauder I et al (1999) Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large cell lymphoma. Cancer Res 59:5386–5391PubMed

16.

ten Berge RL, Meijer CJ, Dukers DF et al (2002) Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99:4540–4546PubMedCrossRef

17.

Muris JJ, Cillessen SA, Vos W et al (2005) Immunohistochemical profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 105:2916–2923PubMedCrossRef

18.

Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working group. J Clin Oncol 17:1244–1253PubMed

19.

The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRef

20.

Mounier N, Briere J, Gisselbrecht C et al (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279–4284PubMedCrossRef

21.

Ansell SM, Arendt BK, Grote DM et al (2004) Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin’s lymphoma. Leukemia 18:616–623PubMedCrossRef

22.

Tolcher AW, Mita A, Lewis LD et al (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198–5203PubMedCrossRef

Title: Prognostic Significance of Survivin and Caspase-3 Immunohistochemical Expression in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP
Authors: Zdravko Mitrović
Ivana Ilić
Igor Aurer
Sandra Bašić Kinda
Ivo Radman
Snježana Dotlić
Radmila Ajduković
Boris Labar
Publication date: 01-06-2011
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-010-9304-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Prognostic Significance of p53 Protein Expression in Early Gastric Cancer

Activation of the PI3K/Akt Pathway Mediates Bone Morphogenetic Protein 2-Induced Invasion of Pancreatic Cancer Cells Panc-1

Well-Differentiated Liposarcoma of the Oesophagus: Clinicopathological, Immunohistochemical and Array CGH Analysis

Involvement of c-Ski Oncoprotein in Carcinogenesis of Cholangiocacinoma Induced by Opisthorchis viverrini and N-nitrosodimethylamine

Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy: Feasibility and Initial Experiences Open MR-Guided High-Dose-Rate (HDR) Prostate Brachytherapy

Combined Antitumor Effect of Ad-bFGF-siRNA and Ad-Vpr on the Growth of Xenograft Glioma in Nude Mouse Model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer